Showing results (201-210 of 242) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2025
Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trialNatalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, et al.Gynecologic Oncology|December 15, 2021
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 studyElizabeth M Swisher, Carol Aghajanian, David M O'Malley, et al.European Journal of Cancer (Oxford, England : 1990)|September 25, 2020
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapyAngelina Tjokrowidjaja, Chee K Lee, Michael Friedlander, et al.Familial Cancer|July 18, 2009
Younger age-at-diagnosis for familial malignant testicular germ cell tumorPhuong L Mai, Bingshu E Chen, Kathy Tucker, et al.The Lancet. Oncology|March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid TumorsJayesh Desai, Hui Gan, Catherine Barrow, et al.Journal for Immunotherapy of Cancer|June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumorsJayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.Gynecologic Oncology|May 25, 2023
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group studyAaron M Praiss, Austin Miller, Judith Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor HistotypeMasataka Takenaka, Martin Köbel, Dale W Garsed, et al.Cancer Research|August 17, 2012
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicinPrue A Cowin, Joshy George, Sian Fereday, et al.Pageof 25